Your Search Returned 46 tagged news reports
Here's a review of protein-protein interaction "hot spots" and their application to drug discovery...This one doesn't break much new ground, but it does provide a number of recent examples, all in one place. People approach this subject because of
Modulators belonging to the patented class have been shown to be necessary for the high-throughput derivation of transgene-free hiPSCs, and for the maintenance, survival and genomic stability of hiPSCs in culture...PSCs for therapeutic applications. "
Over at LifeSciVC , guest blogger Jonathan Montagu talks about small molecules in drug discovery, and how we might move beyond them...Well worth a read, even if he's more sanguine about structure-based drug discovery than I am...These things need the
UCB's research arm UCB NewMedicines has used a new approach to identify small molecules modulators of a biological pathway, for which parenterally administered biologic therapies have proven highly efficacious in patients. The deal will see formation
In the initial term of the agreement Metabolon will carry out small molecule analysis of 10,000 subjects and collaborate with HLI to map changes in the small molecules to end points of disease and gene mutations. HLI cofounders are Dr J Craig Venter,
V Pharma will have a non-exclusive license to use Chiromics' chemical compound library and a screening collaboration to discover and optimize new small molecules against multiple PMV oncology and infectious disease therapeutic targets.
Bayer is licensing an early-stage drug discovery program directed against an epigenetic drug target. Inhibiting epigenetic targets is widely recognized as a promising emerging therapeutic option for cancer and other diseases; however, identifying
FL, January 2, 2013 Scientists from The Scripps Research Institute have revealed an atomic-level view of a genetic defect that causes a form of muscular dystrophy, myotonic dystrophy type 2, and have used this information to design drug candidates
Tomorrow, the World Health Organization will hold a closely watched meeting to sort out the debate over names for biosimilars. Specifically, the agency is being asked to determine whether the system that has been used for small molecule drugs using
These integrated capabilities enable drug discovery teams to investigate and evaluate hypotheses about the chemical or biological behavior of molecules of therapeutic interest in silico prior to costly experimentation. Accelrys predictive sciences